{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:05:04Z","timestamp":1781071504023,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    This case report describes a suspected coagulation disorder induced by cefoperazone\/sulbactam administered for anti-infective therapy. The coagulopathy may be associated with the inhibition of vitamin K synthesis and utilization caused by cefoperazone\/sulbactam. The patient was admitted with severe right thalamic intracerebral hemorrhage complicated by\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    infection and remained on total parenteral nutrition (TPN) due to concomitant gastrointestinal dysfunction. We initiated anti-infective therapy with cefoperazone\/sulbactam at a dose of 2\u00a0g administered intravenously every 12\u00a0h for seven consecutive days. On the eighth day of treatment, the patient developed severe coagulation dysfunction, with prothrombin time (PT) markedly prolonged to 262.9\u00a0s. Cefoperazone\/sulbactam was immediately discontinued, and vitamin K1 along with plasma transfusion was administered. By the third day after intervention, the patient\u2019s coagulation function significantly improved, and PT returned to normal levels. Causality assessment using the Naranjo Adverse Drug Reaction Probability Scale yielded a score of 7, indicating a probable association between the adverse event and cefoperazone\/sulbactam use. This case report emphasizes that cefoperazone\/sulbactam may cause extremely severe coagulation dysfunction, manifested as markedly prolonged PT in this patient. Clinicians should remain vigilant for this potential adverse reaction and closely monitor coagulation parameters during treatment.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1854520","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:32Z","timestamp":1781069852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Extreme and rapidly reversible prolongation of prothrombin time during cefoperazone\/sulbactam therapy in a patient with gastrointestinal dysfunction and parenteral nutrition: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Tian-Rui","family":"Gao","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ping","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Sunshine Union Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2025-004475","article-title":"Severe coagulation dysfunction and active bleeding induced by cefoperazone\/sulbactam in a patient with severe renal insufficiency: a case report","author":"Chen","year":"2025","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/nu13082580","article-title":"Intravenous vitamin K1 for the correction of prolonged prothrombin times in non-bleeding critically ill patients: a prospective observational study","volume":"13","author":"Dahlberg","year":"2021","journal-title":"Nutrients"},{"key":"B3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1055\/s-0042-1742438","article-title":"Effects of inflammation on hemostasis in acutely ill patients with liver disease","volume":"48","author":"Driever","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5005\/jp-journals-10071-24417","article-title":"Cefoperazone-induced coagulopathy in critically ill patients admitted to intensive care unit","volume":"27","author":"Gudivada","year":"2023","journal-title":"Indian J. Crit. Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s40800-019-0100-0","article-title":"Fatal vitamin K-Dependent coagulopathy associated with cefoperazone\/sulbactam: a case report","volume":"6","author":"Hu","year":"2019","journal-title":"Drug Saf. Case Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/antibiotics13090907","article-title":"Comparing the outcomes of Cefoperazone\/sulbactam-based and non-cefoperazone\/sulbactam-based therapeutic regimens in patients with multiresistant Acinetobacter baumannii Infections-A meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Antibiot. (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/sur.2020.468","article-title":"Clinical efficacy and safety of cefoperazone-sulbactam in treatment of intra-abdominal infections: a systematic review and meta-analysis","volume":"22","author":"Lan","year":"2021","journal-title":"Surg. Infect. (Larchmt)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1159\/000531947","article-title":"Micronutrient losses during continuous renal replacement therapy","volume":"147","author":"Lumlertgul","year":"2023","journal-title":"Nephron"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/bcp.70422","article-title":"Cefoperazone\/sulbactam-induced haemolytic anaemia and thrombocytosis: a case report and literature review","volume":"92","author":"Ma","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/IDR.S429706","article-title":"Risk factors for Cefoperazone\/sulbactam-induced coagulation disorder","volume":"16","author":"Miao","year":"2023","journal-title":"Infect. Drug Resist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.2147\/IDR.S534366","article-title":"Construction and validation of a nomogram prediction model for the risk of cefoperazone sodium\/sulbactam sodium-related coagulation disorders","volume":"18","author":"Min","year":"2025","journal-title":"Infect. Drug Resist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/joim.13346","article-title":"The relation between fibrinogen level, neutrophil activity and nucleosomes in the onset of disseminated intravascular coagulation in the critically ill","volume":"290","author":"M\u00fcller","year":"2021","journal-title":"J. Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13054-024-05001-2","article-title":"Vitamin K: a potential missing link in critical illness-a scoping review","volume":"28","author":"Paulus","year":"2024","journal-title":"Crit. Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e939203","DOI":"10.12659\/MSM.939203","article-title":"Effect of cefoperazone\/sulbactam on blood coagulation function in infected emergency department patients and the necessity of vitamin K1 (VK1) preventive intervention: a single-center, retrospective analysis","volume":"29","author":"Shao","year":"2023","journal-title":"Med. Sci. Monit."},{"key":"B16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/jpm15110545","article-title":"Personalized parenteral nutrition in critically ill patients undergoing continuous renal replacement therapy: a comprehensive framework for clinical practice","volume":"15","author":"Sinatra","year":"2025","journal-title":"J. Pers. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3000605251375259","DOI":"10.1177\/03000605251375259","article-title":"Severe delayed coagulopathy caused by cefoperazone\/sulbactam: a case report","volume":"53","author":"Sun","year":"2025","journal-title":"J. Int. Med. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00228-024-03634-4","article-title":"Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: a retrospective case-control study","volume":"80","author":"Wang","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1505653","DOI":"10.3389\/fphar.2024.1505653","article-title":"The clinical features and risk factors of coagulopathy associated with cefoperazone\/sulbactam: a nomogram prediction model","volume":"15","author":"Xu","year":"2025","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:37Z","timestamp":1781069857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":19,"alternative-id":["10.3389\/fphar.2026.1854520"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1854520","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1854520"}}